Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Alnylam Pharmaceuticals Inc
Operating Income
Alnylam Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Operating Income
-$282.2m
|
CAGR 3-Years
30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-12%
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Alnylam Pharmaceuticals Inc's Operating Income?
Operating Income
-282.2m
USD
Based on the financial report for Dec 31, 2023, Alnylam Pharmaceuticals Inc's Operating Income amounts to -282.2m USD.
What is Alnylam Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-12%
Over the last year, the Operating Income growth was 64%. The average annual Operating Income growth rates for Alnylam Pharmaceuticals Inc have been 30% over the past three years , 19% over the past five years , and -12% over the past ten years .